Press Release

CHOSA Oncology AB announces approved re-listing memorandum

May 03, 2023

CHOSA Oncology AB (publ) ("CHOSA" or the "Company"), formerly RhoVac, announces that Spotlight Stock Market ("Spotlight") today approved the relisting memorandum that the Company was required to draw up in connection with the Company's reverse acquisition of the Danish CHOSA ApS.The approval of the re-listing memorandum also confirms that Spotlight considers CHOSA to meet all current listing requirements. As a result, trading in the Company's shares will be re-listed on the ordinary list.

CHOSA, which through the reverse acquisition of CHOSA ApS now owns the licensing rights to the drug development program "iCIP™", has during the spring of 2023 been working on preparing a re-listing memorandum and implementing procedures to ensure that the expanded group complies with the regulations for listed companies on Spotlight Stock Market.

Approved re-listing
Spotlight has now announced the approval of CHOSA's re-listing memorandum and announced the intention to move the Company’s share from the observation list. With the approval of the re-listing memorandum, Spotlight also verifies that CHOSA Oncology meets all current listing requirements.

Sedermera Corporate Finance AB acted as a financial advisor to CHOSA ApS in the reverse acquisition with RhoVac AB. Sedermera has also provided project management to CHOSA Oncology in the re-listing process and assisted in the preparation of the re-listing memorandum.

The re-listing memorandum can be found on the Company's (www.chosaoncology.com), Sedermera's (www.sedermera.se), and Spotlight's (www.spotlightstockmarket.com) respective websites.

CHOSA in short
CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with veteran specialists in oncology; drug development; running clinical trials; regulatory expertise; and business development. CHOSA intends to enter into agreements for partnership or sublicensing of iCIP™.

About iCIP™
CHOSA is focused on late-stage clinical development of iCIP™ (LiPlaCis® and its DRP® companion diagnostic together) to which it has worldwide rights.  The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin.

 

In essence, iCIP™ combines the identification of patients that will benefit from cisplatin treatment with the ability to treat them with higher efficacy and less toxicity. We have strong phase 2b data in metastatic breast cancer, demonstrating that patients selected by DRP® responded better to treatment; have longer progression-free survival; and maybe even an overall longer total survival than those patients who were identified as unlikely to respond well to the treatment. The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Cisplatin therapy after surgery is a gold standard that clearly increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin and who should have something else. This is where the cisplatin DRP is a potential game changer. Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Thus, patients with the 10% highest scores had a 3-year survival of 90% whereas the patients with the lowest 10% score had much lower survival with only 40% surviving 3 years1.

1)  Buhl et al PLOS One doi: 10.1371/journal.pone0194609

DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA.
LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.